Reunion Neuroscience Performance
| REUNDelisted Stock | USD 1.12 0.01 0.90% |
The company holds a Beta of -0.27, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Reunion Neuroscience are expected to decrease at a much lower rate. During the bear market, Reunion Neuroscience is likely to outperform the market. Reunion Neuroscience right now holds a risk of 0.0%. Please check Reunion Neuroscience downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Reunion Neuroscience will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Reunion Neuroscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Reunion Neuroscience is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 64.5 M | |
| Free Cash Flow | -28.2 M |
Reunion |
Reunion Neuroscience Relative Risk vs. Return Landscape
If you would invest 112.00 in Reunion Neuroscience on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Reunion Neuroscience or generate 0.0% return on investment over 90 days. Reunion Neuroscience is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Reunion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Reunion Neuroscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Reunion Neuroscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Reunion Neuroscience, and traders can use it to determine the average amount a Reunion Neuroscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| REUN |
Based on monthly moving average Reunion Neuroscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Reunion Neuroscience by adding Reunion Neuroscience to a well-diversified portfolio.
Reunion Neuroscience Fundamentals Growth
Reunion Stock prices reflect investors' perceptions of the future prospects and financial health of Reunion Neuroscience, and Reunion Neuroscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Reunion Stock performance.
| Return On Equity | -0.86 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | (13.96 M) | |||
| Shares Outstanding | 11.72 M | |||
| Price To Book | 0.49 X | |||
| Price To Sales | 2.80 X | |||
| EBITDA | (17.15 M) | |||
| Cash And Equivalents | 48.13 M | |||
| Cash Per Share | 4.14 X | |||
| Total Debt | 3.37 M | |||
| Book Value Per Share | 1.82 X | |||
| Cash Flow From Operations | (27.92 M) | |||
| Earnings Per Share | (2.51) X | |||
| Total Asset | 29.74 M | |||
| Retained Earnings | (91.48 M) | |||
About Reunion Neuroscience Performance
By examining Reunion Neuroscience's fundamental ratios, stakeholders can obtain critical insights into Reunion Neuroscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Reunion Neuroscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada. Reunion Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 194 people.Things to note about Reunion Neuroscience performance evaluation
Checking the ongoing alerts about Reunion Neuroscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Reunion Neuroscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Reunion Neuroscience is not yet fully synchronised with the market data | |
| Reunion Neuroscience may become a speculative penny stock | |
| Reunion Neuroscience has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (48.49 M) with loss before overhead, payroll, taxes, and interest of (4.29 M). | |
| Reunion Neuroscience currently holds about 48.13 M in cash with (27.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Reunion Neuroscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Reunion Neuroscience's stock is overvalued or undervalued compared to its peers.
- Examining Reunion Neuroscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Reunion Neuroscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Reunion Neuroscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Reunion Neuroscience's stock. These opinions can provide insight into Reunion Neuroscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Reunion Stock
If you are still planning to invest in Reunion Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reunion Neuroscience's history and understand the potential risks before investing.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |